Customized ablations following IOL implantation = spectacle independence

Article

Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence.

Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence, according to Michael Knorz from the University Hospital, Mannheim, Germany.

Dr Knorz bilaterally implanted multifocal IOLs (Tecnis aspheric MF or ReZoom; AMO) into 14 patients with hyperopia and astigmatism of more than 2 D. A femtosecond-laser flap (IntraLase FS-60) of 100 microns and 9 mm was created immediately prior to lens surgery without lifting it. In eyes implanted with the Tecnis lens, a wavefront-guided ablation was performed, meanwhile in eyes implanted with the ReZoom lens, a standard ablation was performed with the Visx Star S4 (AMO) to fine tune the refraction.

Following implantation of the IOLs, average sphere was +0.85 and average cylinder was +1.04. After laser enhancement, sphere was +0.12 and cylinder +0.23. Higher order aberrations decreased significantly from 0.6 after IOL implantation to 0.32 after laser correction. No patient required spectacles postoperatively.

Dr Knorz believes that customized ablations following IOL implantation allows most patients to achieve spectacle independence and decreases the incidence of higher order aberrations.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.